Jazz loses appeal, will have patent delisted from the Orange Book

The US Court of Appeals for the Federal Circuit is upholding an injunction that states that a patent related to Jazz Pharmaceuticals’ narcolepsy drug should be delisted from the FDA’s generic drug compendium known as the Orange Book.